NKCFO LLC’s Moderna MRNA Stock Holding History

NKCFO LLC’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,500	Closed	-$258K	–	118
2022 Q1	$258K	Sell	1,500 -500	-25%	-$84.2K	0.08%	61
2021 Q4	$508K	Buy	+2,000	New	+$585K	0.16%	44

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NKCFO LLC's MRNA Position: Q2 2022 in Review

NKCFO LLC sold out of Moderna (MRNA) in Q2 2022, closing a stake of 1,500 shares — an estimated $258K sold.

NKCFO LLC first reported a position in MRNA in Q4 2021 and held it in 2 quarters. The position peaked at $508K in Q4 2021. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

NKCFO LLC reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
NKCFO LLC sold 1,500 Moderna shares in Q2 2022, an estimated $258K.
NKCFO LLC first reported a position in Moderna in Q4 2021 and held it in 2 quarters.
NKCFO LLC's Moderna position peaked at $508K in Q4 2021.
981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on NKCFO LLC's 13F filing for Q2 2022, filed 8 Jul 2022.